How long does a heat-killed Vibrio vaccine take to work in shrimp?

Allow three to five days. Trial data showed no significant difference between vaccinated and control shrimp at 24 hours. Separation appeared by day 3, immune parameters peaked around days 5 to 7, and the protective window was still measurable at day 7. Vaccinating during an active outbreak is too late to help.

Is a higher dose of heat-killed Vibrio parahaemolyticus always better?

No. The higher dose (1 x 10^7 CFU/mL, HVp7) produced stronger and longer-lasting immune markers, but only about four percentage points more survival than the lower dose (1 x 10^5 CFU/mL, HVp5): 70.8% versus 66.7%. The high dose also caused larger swings in haemolymph glucose and lactate. The low dose delivered most of the protection with a steadier metabolic profile, which generally makes it the better commercial choice.

Does a heat-killed Vibrio parahaemolyticus vaccine protect against AHPND?

No. The isolate used in this research was a non-AHPND strain that lacked the pVA1 virulence plasmid and the PirAB(Vp) toxin genes. The results describe protection against ordinary Vibrio parahaemolyticus infection, not against acute hepatopancreatic necrosis disease. Farms should PCR-screen isolates for pirA(Vp) and pirB(Vp) before assuming any Vibrio vaccine matches their mortality problem.

Why use heat-killed bacteria instead of a live vaccine in shrimp?

Heat-killed cells keep the heat-stable pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide, peptidoglycan and flagellar proteins that shrimp pattern-recognition receptors detect, so they still trigger a full innate immune response. Because autoclaving at 121 degrees Celsius for 20 minutes kills the cells, they cannot replicate, cannot cause disease, cannot shed into pond water, and cannot exchange genetic material with environmental Vibrio.

Does immune activation from a heat-killed Vibrio vaccine stress shrimp?

There is a cost, but it is bounded. Haemolymph glucose and lactate shifted during the first five days after injection, with the high-dose group showing a larger excursion. Lactate returned to baseline by day 7 and stayed there, and glucose recovered in all groups, which indicates physiological adaptation rather than chronic metabolic stress.

What is the biggest obstacle to using heat-killed Vibrio vaccines on a shrimp farm?

Delivery. Efficacy was demonstrated by intramuscular injection of 20 microlitres into the ventral sinus of the cephalothorax, which is precise but impossible to apply at production scale. Validating immersion or oral administration at equivalent doses is the critical next step before this approach becomes commercially practical.

Which immune parameters should a shrimp farm monitor after vaccination?

Phagocytic activity and bacterial clearance efficiency. In trial data these two measures separated vaccinated shrimp from controls earliest, with differences visible at day 1, and they tracked most closely with survival. Total haemocyte count alone is a weak indicator because it reflects only how many cells are circulating, not their viability, activation state or functional capacity.

How is heat-killed Vibrio parahaemolyticus prepared?

The bacterium is grown in tryptic soy broth supplemented with 2% NaCl at 28 degrees Celsius for 16 hours, washed twice in 0.85% saline by centrifugation, then heat-inactivated by autoclaving at 121 degrees Celsius for 20 minutes. Concentrations refer to viable bacterial counts measured before heat inactivation.

What hepatopancreas changes are seen in vaccinated shrimp after Vibrio challenge?

Unvaccinated controls showed severe damage: epithelial cells detached from the basal lamina, sloughing into the lumen, thinned and broken cell walls, and very few vacuoles or lumina. Vaccinated shrimp retained largely intact hepatopancreas architecture with abundant vacuoles and well-defined lumina. Melanization, the pigmented encapsulation response that kills invading bacteria, was observed in the high-dose group.

Heat-Killed Vibrio Vaccine in Shrimp: 70.8% Survival vs 45.8%

Q: Does a heat-killed Vibrio parahaemolyticus vaccine work in white shrimp?

Yes. In controlled challenge trials with Litopenaeus vannamei, shrimp vaccinated with heat-killed Vibrio parahaemolyticus reached survival rates of 66.7% (low dose, 1 x 10^5 CFU/mL) and 70.8% (high dose, 1 x 10^7 CFU/mL) at seven days post-challenge, compared with 45.8% in unvaccinated saline controls. Both vaccinated groups also showed higher haemocyte counts, phenoloxidase activity, respiratory burst, lysozyme activity, phagocytic activity and bacterial clearance efficiency.

Heat-killed Vibrio parahaemolyticus (HVp) works as an immunostimulant in Pacific white shrimp (Litopenaeus vannamei). In controlled trials, a single intramuscular dose raised haemocyte counts, phenoloxidase activity, respiratory burst, lysozyme activity, phagocytosis and bacterial clearance within three to five days, and held those gains for at least a week. When vaccinated shrimp were later challenged with live V. parahaemolyticus, survival reached 66.7% at the low dose and 70.8% at the high dose, against 45.8% in unvaccinated controls. The vaccinated groups also kept steadier haemolymph glucose and lactate profiles and showed far less hepatopancreas damage, which suggests the immune activation came without a heavy metabolic price.

One boundary matters here. The strain used was a non-AHPND isolate. These results describe protection against ordinary V. parahaemolyticus infection, not against acute hepatopancreatic necrosis disease.

Why vibriosis keeps breaking shrimp farms

Shrimp farming is the fastest-growing animal-protein sector on the planet, and Litopenaeus vannamei sits at the centre of it. The species earns its place: fast growth, tolerance of a wide salinity and temperature band, uniform size at harvest, and a temperament that suits intensive stocking. That same intensification is what makes it fragile.

Disease is the single largest constraint on the industry, and Vibrio species are the usual suspects. Among them, Vibrio parahaemolyticus gets the most attention. Partly that attention is deserved, partly not.

Here is the distinction that too many farm-level decisions still blur. V. parahaemolyticus is a Gram-negative marine bacterium found throughout estuarine and coastal water. Most environmental isolates are unremarkable. A subset carries a roughly 70-kbp plasmid, pVA1, which encodes the binary toxin PirABVp. Those are the AHPND-causing strains: the ones that produce a pale, shrunken hepatopancreas, sloughing of hepatopancreatic epithelium, and mortality that can empty a pond in days.

Delete the toxin genes, or lose the plasmid, and the bacterium stops producing AHPND lesions. So “we have V. parahaemolyticus in the pond” and “we have AHPND” are two different statements, and they call for two different responses. Much of the chronic, nagging vibriosis that erodes feed conversion and pushes up daily mortality is non-AHPND. That is what we are talking about here.

Antibiotics were the first answer and remain a bad one. Residues in harvest animals, selection for resistant bacteria, and environmental loading have pushed the industry toward alternatives: probiotics, immunostimulants, bacteriophages, vaccines. Inactivated whole-cell vaccines are the oldest idea in the folder, and for good reason. They are cheap to make, stable, and impossible to shed.

What “heat-killed” actually means

The preparation is blunt. Grow the bacterium in tryptic soy broth with 2% NaCl, wash the cells in saline, then autoclave at 121 °C for 20 minutes. Nothing survives that.

What does survive is the thing you care about, namely the pathogen-associated molecular patterns, or PAMPs. Lipopolysaccharide, peptidoglycan, flagellar proteins and β-glucan-type structures on the cell wall are heat-stable. Kill the bacterium and its molecular signature is still legible to the shrimp.

That signature is what pattern-recognition receptors on haemocyte surfaces read. Binding triggers the prophenoloxidase cascade, degranulation, phagocytosis and the release of antimicrobial peptides. Heat-killed cells deliver the full “this is a bacterium” alarm without any risk of establishing an infection. For a farm, that risk profile is most of the argument.

Shrimp have no adaptive immune system in the vertebrate sense: no antibodies, no classical memory. For years that was read as “vaccination is pointless in shrimp.” It is not. Crustaceans show immune priming, where a first exposure leaves the innate system in a heightened state so a second encounter gets handled faster and with less collateral damage. Heat-killed cells are a clean way to deliver that first exposure.

How the trial was set up

Three groups, run in triplicate tanks:

Group	Treatment	Approximate dose per shrimp
Control	Sterile saline	—
HVp5	Heat-killed V. parahaemolyticus from a 1 × 105 CFU/mL suspension	2 × 103 CFU
HVp7	Heat-killed V. parahaemolyticus from a 1 × 107 CFU/mL suspension	2 × 105 CFU

Shrimp averaged about 6 g at stocking and were held at 20 ppt salinity, 28 ± 1 °C, pH 7.1–7.6, fed a commercial pellet twice daily. Every animal was confirmed to be in intermolt stage C, the metabolically stable window between moults. That detail matters, because moulting itself swings immune and metabolic parameters hard enough to bury a treatment effect.

The two doses were not picked at random. A preliminary challenge established the LD50 of the live isolate by Karber’s method, then the low dose was set below it and the high dose above it. That gives a genuine dose-response read rather than two arbitrary numbers.

Each shrimp received 20 µL into the ventral sinus of the cephalothorax. Sampling ran at days 0, 1, 3, 5 and 7, six shrimp per group per time point. Immune measures covered total haemocyte count (THC), differential haemocyte count (hyaline, semi-granular and granular cells), phenoloxidase activity, respiratory burst, lysozyme activity, phagocytic activity and bacterial clearance efficiency, plus haemolymph glucose and lactate.

A challenge test followed at day five, chosen because immune parameters had reached their earliest plateau by then. Shrimp were injected with live V. parahaemolyticus at 2 × 105 CFU/shrimp and mortality was recorded daily for seven days.

The cellular response: more haemocytes, and the right kinds

Nothing happened on day one. All four haemocyte measures, meaning total count, hyaline cells, semi-granular cells and granular cells, were statistically indistinguishable across groups. Anyone sampling at 24 hours would have concluded the vaccine did nothing.

That lag is the first practical lesson. Immune priming takes time, and a farm that vaccinates and then challenges on day two will see nothing at all.

From day three the groups separated, and they separated differently.

HVp5 responded early, with hyaline, semi-granular and granular cells all rising above control by days 3 to 5. HVp7 responded later but harder and longer: by day 7, total haemocyte count and all three subpopulations in HVp7 were significantly above both HVp5 and control.

Read together, the low dose buys speed and the high dose buys magnitude and duration. Which one a farm wants depends on its risk window. If disease pressure typically arrives within a week of stocking, the low dose fits better. If the threat is a month out, the high dose’s longer tail matters more.

The subpopulation split is the more informative part. Semi-granular and granular cells are the working end of crustacean cellular immunity, handling phagocytosis, encapsulation, melanization and the release of antimicrobial molecules. Their sustained elevation from day 3 through day 7 is not a transient stress artefact. It is prolonged activation of the cellular arm.

Worth stating plainly, though: a higher total haemocyte count only tells you how many cells are circulating. It says nothing about viability, activation state, or what those cells can actually do. That is why the functional assays matter more than the count, and why the next section is where the real evidence sits.

The humoral arm: phenoloxidase, respiratory burst, lysozyme

Phenoloxidase (PO) sits at the centre of the crustacean defence cascade. Its active form drives melanization, the blackening that walls off invaders, and generates the reactive intermediates that kill them. PO activity dipped on day one across all groups, since handling stress does that, then climbed. By day 3, both vaccinated groups were significantly above control. By day 5, HVp7 remained elevated while HVp5 sat in an intermediate position. By day 7 the control had caught up and the difference had closed.

Respiratory burst (RB) measures superoxide production: the deliberate, controlled release of reactive oxygen species used to kill phagocytosed bacteria. Here the dose separation held longer. On day 3, HVp7 beat HVp5, and both beat control. On day 5, both vaccinated groups stayed above control. On day 7, HVp7 was still significantly above control, with HVp5 intermediate.

Lysozyme is the enzyme that chews through peptidoglycan in bacterial cell walls, and it is one of the more conserved defence molecules across animal immunity. No difference on day one, then by day 3 the HVp7 group was significantly above both control and HVp5, and that advantage held into day 5.

The pattern across all three is consistent. Day one null, day three separation, and a high-dose advantage that outlasts the low-dose one. Heat-killed cells carrying intact PAMPs drive this: the receptors see the bacterial signature and respond, even though the cells are dead.

Phagocytosis and clearance: the assays that predict survival

If you only have budget for two measurements, measure these two.

Phagocytic activity rose over time in both vaccinated groups, and both were above control by day 1, which is the earliest separation in the entire dataset. By day 3, HVp7 exceeded HVp5, and both exceeded control. On day 5, HVp5 peaked and actually surpassed HVp7. By day 7, HVp7 remained significantly above control while HVp5 fell back to an intermediate position.

Bacterial clearance efficiency, meaning how fast the animal removes injected bacteria from its haemolymph, improved in both vaccinated groups across the whole study period. Day 1: both above control. Day 3: HVp5 peaked, above both HVp7 and control. Day 5: HVp7 reached its maximum, above HVp5 and control. Day 7: both still above control, no difference between them.

Note the crossover. HVp5 peaks early on clearance, HVp7 peaks late. The two doses are not simply more and less of the same thing; they are differently shaped response curves stacked in time. In a pond, where exposure is rarely a single clean event, that staggered profile may be more useful than either dose alone.

The metabolic bill: glucose and lactate

This is the section most vaccine write-ups skip, and it is the one that decides whether an immunostimulant is commercially viable.

Activating an immune system costs energy. In crustaceans under combined stress, that cost shows up as carbohydrate mobilisation: glycogen breaks down, haemolymph glucose rises, and when demand outruns oxygen supply the animal shifts to anaerobic glycolysis and lactate accumulates. Glucose and lactate are therefore the receipt for immune activation, and stress markers as well. An immunostimulant that protects shrimp but leaves them metabolically wrecked has traded one problem for another.

Glucose first. On day 1, HVp7 ran significantly below control, with HVp5 intermediate, which fits with rapid immune activation consuming circulating glucose. By day 3, HVp7 glucose had risen significantly above both other groups. On day 5, HVp7 dropped sharply to its lowest value, significantly below both HVp5 and control. By day 7 all groups had recovered, with control highest, HVp5 significantly lower, HVp7 intermediate.

Lactate second. No differences on day 1. On day 3, HVp7 peaked, significantly above HVp5 and control. On day 5 both vaccinated groups remained elevated above control, with HVp7 above HVp5. By day 7, lactate was back to baseline in all three groups with no significant differences.

The disturbance resolved. Lactate returned to control values by day 7 and stayed there, which argues against chronic metabolic stress. Both doses appear to fund immune activation without imposing a lasting energy debt, with HVp5 doing it more smoothly and HVp7 taking a larger but still self-limiting excursion.

That difference has a management reading. HVp5 kept glucose stable throughout, which makes it the safer choice in ponds already carrying other stressors such as low dissolved oxygen, high ammonia, nitrite spikes or heavy handling. HVp7 produces a stronger immune response and a bumpier metabolic ride.

Survival after challenge

Five days after vaccination, shrimp were injected with live V. parahaemolyticus at 2 × 105 CFU/shrimp. Mortality was recorded for seven days.

Group	Survival at 7 days post-challenge
Control (saline)	45.8 ± 4.2%
HVp5	66.7 ± 4.2%
HVp7	70.8 ± 4.2%

Both vaccinated groups were significantly above control. HVp5 cut mortality by roughly a third, HVp7 by a little more. The gap between the two doses was modest and, at the end point, not the interesting part. The interesting part is that the low dose achieved most of the protection.

The shapes of the decline differed too. Controls fell steadily and kept falling through 168 hours. Vaccinated groups declined far more slowly and then flattened out, HVp5 from 96 hours onward and HVp7 from 120 hours onward. That plateau is the signature of an immune system that has caught up with the pathogen. The control group never plateaus because it never catches up.

Two caveats belong here. Challenge was by injection, which bypasses the gut and gill barriers an immersion or oral challenge would have to cross, so these survival figures represent a best case for the pathogen rather than a worst case. And challenge mortality in general swings with dose, exposure route and background stressors such as ammonia, salinity and nitrite. A farm running marginal water will not reproduce these numbers.

What the hepatopancreas looked like

Histology is where the survival numbers stop being abstract.

In unvaccinated controls after challenge, the hepatopancreas was badly damaged. Epithelial cells had detached from the basal lamina and sloughed into the lumen, cell walls were thinned and frequently broken, and very few vacuoles or lumina remained. That is the classic V. parahaemolyticus picture.

In both vaccinated groups, tissue architecture was largely preserved. Epithelial cells still contained numerous vacuoles and well-defined lumina, the structural markers of a hepatopancreas still doing its job of digestion and nutrient storage. Occasional sloughing and detachment remained, so protection was partial rather than absolute. The difference from control was not subtle.

In the HVp7 group, melanization was visible: the dark pigmented encapsulation response that walls off and kills invading bacteria. Seeing it in tissue is direct visual confirmation that the immune cascade the blood assays measured was actually operating in the organ that matters.

The hepatopancreas is the shrimp’s digestive gland, storage depot and metabolic hub combined. Saving it is the difference between an animal that survives and an animal that survives and still grows.

What this means on a farm

Timing is the dominant variable. Nothing measurable happened on day one, and protection depends on vaccinating at least three to five days before expected disease pressure. Vaccinating during an active outbreak is too late.

The low dose is the better commercial bet. HVp5 delivered most of the survival benefit with a smoother metabolic profile and less disturbance to glucose handling. HVp7 produced stronger immune markers but only about four percentage points more survival. In most pond conditions, that trade favours HVp5.

Delivery is the unresolved problem. This trial used intramuscular injection, which is precise and repeatable and utterly impractical at pond scale. Vaccinating a million post-larvae by hand is not a workflow. Until immersion or oral delivery is validated at comparable doses, the gap between efficacy and deployability is the real constraint, and it is a formulation problem rather than an immunological one.

Screen your isolate before you act. Protection here was against a non-AHPND strain. If your mortality is driven by a pVA1-positive, PirABVp-carrying strain, this approach is not addressing your problem. PCR screening for pirAVp and pirBVp is cheap and is the first thing to do when mortality starts.

Inactivated vaccines also fit resistance management. No live organism, no shedding, no recombination with environmental Vibrio, no selection pressure on the wider bacterial community. That is a meaningfully different risk profile from either antibiotics or live attenuated products.

Takeaways

Heat-killed V. parahaemolyticus primes shrimp innate immunity with a measurable lag: no effect at 24 hours, clear separation by day 3, peak around days 5 to 7.
Both doses raised haemocyte counts, phenoloxidase, respiratory burst, lysozyme, phagocytosis and bacterial clearance. The low dose acts faster, the high dose acts longer.
Survival after live challenge reached 66.7% (HVp5) and 70.8% (HVp7) versus 45.8% in controls.
Glucose and lactate disturbances were transient and resolved by day 7, indicating immune activation without chronic metabolic cost.
Hepatopancreas architecture was largely preserved in vaccinated shrimp, with melanization visible in the high-dose group.
Protection was demonstrated against a non-AHPND isolate. This is not an AHPND solution.
Injection delivery proved efficacy but not practicality. Validating immersion and oral routes is the next hurdle.

FAQ

Does a heat-killed Vibrio vaccine actually work in shrimp? Yes. In controlled challenge trials, shrimp vaccinated with heat-killed V. parahaemolyticus showed survival rates of 66.7% and 70.8% at seven days post-challenge, compared with 45.8% in unvaccinated controls.

How long does it take for the vaccine to work? Allow three to five days. No immune parameters differed from control at 24 hours; significant separation appeared by day 3 and peaked around days 5 to 7.

Is the higher dose always better? No. The higher dose produced stronger and longer-lasting immune markers but only about four percentage points more survival, along with larger swings in haemolymph glucose and lactate. The lower dose offers most of the protection with a steadier metabolic profile.

Does this protect against AHPND? No. The isolate used in this work was a non-AHPND strain lacking the pVA1 plasmid and the PirABVp toxin genes. These results describe protection against ordinary V. parahaemolyticus infection.

Why use killed bacteria instead of a live vaccine? Heat-killed cells retain the heat-stable molecular patterns that shrimp immune receptors recognise, so they still trigger a full innate response. They cannot replicate, cannot cause disease, and cannot shed into pond water or exchange genetic material with environmental Vibrio.

Does immune activation stress the shrimp? It carries a cost, but a bounded one. Glucose and lactate shifted during the first five days, then returned to baseline by day 7, which indicates physiological adaptation rather than chronic stress.

What is the biggest obstacle to using this on a farm? Delivery. Efficacy was demonstrated by intramuscular injection, which cannot be applied at production scale. Validating immersion or oral administration at equivalent doses is the critical next step.

Which immune parameter should a farm monitor? Phagocytic activity and bacterial clearance efficiency. They separated vaccinated from control animals earliest and track most closely with survival. Total haemocyte count alone is a weak indicator because it says nothing about what the cells can do.